Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes | Latest News RSS feed Jetpack

Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes - Latest News


BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * MER... read more

Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan

Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Steglatro (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 or SGLT2 inhibitor, ... read more

Roche : EMA committee recommends seven therapies from Roche, GSK, MSD and more

A final decision on the approval ... adults over 50. MSD scored three recommendations off the back of its oral SGLT2 inhibitor Steglatro (ertugliflozin), which was backed on its own for the treatment ... read more

Looking for another news?


Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck and Pfizer announced that the FDA approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, the fixed-dose combination STEGLUJAN ... glycemic control ... read more


Pfizer Ltd (PFIZ.BO)

Nov 10 (Reuters) - Pfizer Ltd ::Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year.Sept quarter revenue from operations 5.71 billion rupees versus 5.58 billion ... read more

Pfizer Ltd (PFIZ.NS)

Nov 10 (Reuters) - Pfizer Ltd ::Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year.Sept quarter revenue from operations 5.71 billion rupees versus 5.58 billion ... read more

BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla

Dec 22 (Reuters) - Agile Therapeutics Inc: * AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY * AGILE THERAPEUTICS - CRL ... read more

BRIEF-Party City Announces Repurchase Of Common Stock

Dec 22 (Reuters) - Party City Holdco Inc: * PARTY CITY ANNOUNCES REPURCHASE OF COMMON STOCK * PARTY CITY HOLDCO INC - PURCHASE OF 19.8 MILLION SHARES OF COMMON STOCK FOR $242 MILLION FROM ADVENT-PARTY ... read more

BRIEF-Qualcomm Board Rejects Director Nominees Assembled By Broadcom, Silver Lake Partners (QCOM, AVGO)

Dec 22 (Reuters) - Qualcomm Inc: * QUALCOMM BOARD UNANIMOUSLY REJECTS DIRECTOR NOMINEES ASSEMBLED BY BROADCOM AND SILVER LAKE PARTNERS * QUALCOMM - FOLLOWING RECOMMENDATION OF BOARD'S GOVERNANCE COMMI... read more

Merck and : - FDA APPROVES SGLT2 INHIBITOR STEGLATRO AND FIXED-DOSE COMBINATION STEGLUJAN FOR ADULTS WITH TYPE 2 DIABETES

an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets. STEGLATRO is indicated as an adjunct to diet and exercise to ... read more

Pfizer Ltd (PFIZ.BO)

Nov 10 (Reuters) - Pfizer Ltd ::Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year.Sept quarter revenue from operations 5.71 billion rupees versus 5.58 billion ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us